Company intelligence / Profile preview
Alanis Therapeutics
San Diego, California, USAalanistx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Alanis Therapeutics is developing a first-in-class antagonist monoclonal antibody targeting jagged 1 on osteoblasts within the bone marrow stroma. This approach aims to disrupt oncogenic signaling via the Notch pathway that drives leukemic stem cells in high-risk MDS/AML. The company has demonstrated preclinical proof-of-concept and received a $2M SBIR Phase 2 award to advance its lead candidate toward clinical trials. Manufacturing partnership with KBI Biopharma is accelerating IND-enabling activities using SUREmAb™ technology. Additional pipeline assets include multi-specific antibodies for oncology and autoimmunity[1][2][3].
- Therapeutic areas
- OncologyHematology
- Modalities
- Monoclonal antibodyAntibody (general)Biologic (platform includes bi-/tri-specific antibodies and NK cell engagers)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
KBI Biopharma – contract development & manufacturing organization partner for lead mAb program using SUREmAb™ technology[3]Columbia University – scientific collaboration/licensing of IP related to target/biomarker discovery in MDS/AML [2]AvantGen – ongoing licensing/collaboration for access to engineered antibody platforms/assets [1]
Beyond the preview
Go deeper on Alanis Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alanis Therapeutics.